PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Barbara Wirostko, Altheos – Presents at 3rd Ocular Diseases & Drug Discovery Conference Boston, MA - Barbara Wirostko, Chief Medical Officer of Altheos will give a featured presentation at GTCbio’s 3rd Ocular Disease & Drug Discovery Conference, May 26-27, in Boston, MA
Barbara Wirostko, Altheos – Presents at 3rd Ocular Diseases & Drug Discovery Conference Boston, MA

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2011/03/03 - Barbara Wirostko, Chief Medical Officer of Altheos will give a featured presentation at GTCbio’s 3rd Ocular Disease & Drug Discovery Conference, May 26-27, in Boston, MA.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Barbara Wirostko, M.D., Chief Medical Officer, Altheos, will give a featured presentation on Rho Kinase Inhibitors for Glaucoma: IOP Lowering Plus at GTC’s 3rd Ocular Diseases & Drug Discovery Conference on May 26-27, 2011 in Boston, MA.

Barbara Wirostko will present her topic on glaucoma treatment, discussing how Rho kinase (ROCK1 and ROCK2) is a serine/threonine kinase that serves as an important downstream effector of Rho GTPase. This class of kinases plays a key role in regulating the contractile tone of smooth muscle tissue through actin stress fibers via the phosphorylation of MLC (myosin light chain) in a calcium-independent manner. Myosin phosphorylation and the resultant increase in the contractile state is regulated through ROCK and subsequent vascular smooth muscle mediators such as Nitric oxide and endothelin. Rock inhibition leads to the relaxation of smooth muscle fibers. Experimental evidence indicates that inhibiting ROCK activity through topical and systemic ROCK I s could be beneficial for the treatment of increased intraocular pressure in patients with glaucoma. The rationale stems from data suggesting that both ROCK and Rho GTPase inhibitors can increase aqueous humor drainage via trabecular meshwork smooth muscle and ciliary muscle relaxation.

GTC’s 3rd Ocular Diseases conference will also bring together leaders from GlaxoSmithKline, ORA, the John A. Moran Eye Center, Santen, Allergan, and more. Updates on age-related macular degeneration, recent drug developments and mechanisms, rho kinase inhibitors, and the future of ocular disease therapeutics will be addressed and discussed.

GTCbio’s 3rd Ocular Disease & Drug Discovery Conference will provide cutting edge information and a chance to exchange ideas from leading experts in the field.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Barbara Wirostko, Altheos – Presents at 3rd Ocular Diseases & Drug Discovery Conference Boston, MA

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)